

# Sharda Cropchem Limited

Tel. : +91 22 66782800  
FAX : +91 22 66782828 / 66782808  
E-mail : office@shardaintl.com  
Regd. Office : Prime Business Park, Dashrathlal Joshi Road, Vile Parle (W),  
Mumbai - 400056, India.  
www.shardacropchem.com



ISO 9001: 2015 Reg. No: 702949  
CJN: L51909MH2004PLC145007



12<sup>th</sup> May, 2023

To,

<b>National Stock Exchange of India Limited</b> Exchange Plaza, 5th Floor, Plot No. C/1, G-Block, Bandra Kurla Complex, Bandra (E), Mumbai – 400 051  <b>Trading Symbol: SHARDACROP</b>	<b>BSE Limited</b> Phiroze Jeejeebhoi Tower, Dalal Street, Mumbai – 400 001  <b>Scrip Code: 538666</b>
--	---

**Subject: Investors / Analyst's Presentation for the Quarter and Year ended 31<sup>st</sup> March, 2023**

Dear Sir/Madam,

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Listing Regulations), we are enclosing herewith the presentation to be made to the Investors/Analysts on the Financial Results of the Company for the quarter and year ended 31<sup>st</sup> March, 2023.

The presentation is also being uploaded on the website of the Company [www.shardacropchem.com](http://www.shardacropchem.com) in accordance with Regulation 46 of the Listing Regulations.

We request you to take the same on record.

Yours Sincerely,

---

**Jetkin Gudhka**  
**Company Secretary &**  
**Compliance Officer**

**Encl.: As above**



*Sharda Cropchem Limited*



**EXPLORE...  
EMERGE...  
ENHANCE**

**Investor Presentation**

May 2023

This presentation and the accompanying slides (the “Presentation”), which have been prepared by **Sharda Cropchem Limited** (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on in connection with any contract or binding commitment what so ever. No offering of securities of the Company will be made except by means of a statutory offering document containing detailed information about the Company.

This Presentation has been prepared by the Company based on information and data which the Company considers reliable, but the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded

Certain matters discussed in this Presentation may contain statements regarding the Company’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. These risks and uncertainties include, but are not limited to, the performance of the Indian economy and of the economies of various international markets, the performance of the industry in India and world-wide, competition, the company’s ability to successfully implement its strategy, the Company’s future levels of growth and expansion, technological implementation, changes and advancements, changes in revenue, income or cash flows, the Company’s market preferences and its exposure to market risks, as well as other risks. The Company’s actual results, levels of activity, performance or achievements could differ materially and adversely from results expressed in or implied by this Presentation. The Company assumes no obligation to update any forward-looking information contained in this Presentation. Any forward-looking statements and projections made by third parties included in this Presentation are not adopted by the Company and the Company is not responsible for such third party statements and projections.



**About Sharda Cropchem Limited**

“We are a fast-growing global agrochemicals company with a peer position in the generic crop protection chemicals industry. Our vast and growing library of dossiers and IPRs provide us solid foundations for growth in the global marketplace, especially in Advanced Markets such as Europe, North America and Latin America. It equips us with the ability to operate in a diversified range of formulations and generic active ingredients space globally”



Intellectual Property (IP) driven company engaged in marketing and distribution of wide range formulations and generic active ingredients



### Asset Light Business Model

Efficiently channelizing time and resources for strengthening core competency of identifying generic molecules and registration opportunities which offer scalable growth with limited capital requirements



### Large Pipeline of Registrations\*

Procured 2,821 registrations. Additionally, it has filed 1,143 applications for registrations globally pending at different stages



### Diversified Sourcing Arrangements

Enduring relationship with multiple manufacturers and formulators enables to source and supply formulations or generic active ingredients at competitive prices



### Consistently Increasing Global Presence

With diversified range of product portfolio, Company has grown by expanding business operations in 80+ countries, across Europe, NAFTA, Latin America and ROW



### Widespread Distribution Network

Presence in the entire agrochemical value chain with 500 third party distributors and 400+ sales force serving the Company's esteemed clientele in 80+ countries

Company's apt domain knowledge and experience gives substantial competitive advantage for expanding business in existing markets and new geographies

# Asset Light Business Model

## Overall Agrochemical Value Chain

Sharda's Operating Area



### SHARDA CROPCHEM'S ASSET LIGHT BUSINESS MODEL

Focus on identification of generic molecules, preparing dossiers, seeking registrations, marketing & distributing formulations through third-party distributors and/or own sales force

Manufacturing of AIs and formulations is outsourced

- Highly flexible operating model resulting in
- Overall cost competitiveness
  - Efficient management of fluctuating market demand across various geographies
  - Offering wide range of formulations and AIs

Acts as a key differentiator from an innovator company, allowing the Company to save its capital, time and resources on R&D

# Increasing Global Presence having a Widespread Distribution



**Presence**  
**80+ countries**

across Europe, NAFTA,  
LATAM & RoW

**Global Resource Deployment**  
**500+**

**Distributors**  
**525+**

**CAPEX incurred in FY23\***  
**Rs. 355 Cr.**



*Over the years, we've built a strong brand franchise within our global markets; we are benefiting through the economies of scale in our portfolio and leveraging value of our supply chain to deliver value to our customers across geographies*

Company has gained a great deal from globalization, including new customers and diverse geocentric revenue streams. Over the years, we have mastered flexibility and adopted innovative ways to grow our business overseas

In addition to newer markets, the wide global presence has allowed us to find new, specialised sales and local marketing talent.

**Successfully adopted a factory-to-farmer approach to become a one-stop solution provider to our global customers**

Strengthening and widening the sales force in Europe, USA, Canada, Mexico, Colombia, South Africa, India, and rest of the world, in addition to third party distributors with a goal to enhance its presence in the agrochemical value chain

It enables the Company to penetrate its formulations and generic active ingredients in various countries backed by the third-party distributors and presence of its own sales force



\* Plus related revenue expenditure on registrations





## THE SHARDA ADVANTAGE

Global Reach

Wide Product Range

Healthy relationships with suppliers

Quality with Affordability

Faster Sales Service

One Stop Solution Provider for Crop Care Products

# Way Forward

## Forward Integration - Build Sales Force

- Leverage market presence and execution capabilities
- Adopt the factory to farmer approach and be a one stop solution provider
- Strategy on ground in different regions of NAFTA, Europe, LATAM and other key markets in ROW

## Expand & Strengthen Distribution Presence


- Expand geographical reach using existing library of dossiers
- Two-fold strategy of further penetrating existing markets and entering new markets

## Continual Investment in Product Registrations

- Continue to identify generic molecules going off patent
- Investing in preparing dossiers and seeking registrations in own name


## Focus on Operational Efficiencies

- Accelerated focus on revenue generating investments
- Margin improvements
- Better cost management and eliminate NVAs



# Industry Outlook and Growth Drivers

Global crop protection chemicals market value (In Billion USD) – CAGR of 3.5%



## INDUSTRY DRIVERS

**1**  
A growing population: the global population is set to **increase by 1.2 billion by 2030 and 2 billion by 2050**, while the middle class will more than double to 4.9 billion by 2030



**2**  
A growing middle class fuels demand for increased food and protein production, **which in turn drives demand for grain to support growth**



**3**  
Fewer arable acres per capita means that products need to continue to maximise farmer yields; **arable land is expected to decrease from half an acre per person today to less than one-third of an acre per person by 2050**



**Mr. Ramprakash V. Bubna**  
Chairman & Managing Director

- Holds a Bachelor's Degree of Technology in Chemical Engineering from IIT, Bombay
- He has over 53 years of experience in chemicals, agrochemicals and related businesses
- He is responsible for the Company's overall business operations and strategy



**Mr. Ashish Bubna**  
Whole Time Director

- Holds a Bachelor's Degree in Commerce from the University of Mumbai
- Over 30 years of experience in marketing of chemicals, agrochemicals and related businesses.
- Instrumental in strategizing early investment in product registrations and building the library of product dossiers.
- Responsible for marketing, procurement, registrations and logistics functions of the agrochemical business.



**Mr. Manish Bubna**  
Whole Time Director

- Holds a Bachelor's Degree in Chemical Engineering from the Department of Chemical Technology, Bombay University.
- Over 28 years of experience in chemicals, agrochemicals and related businesses
- Spearheaded the Company's foray into the conveyor belt and general chemicals business
- Also oversees the information technology, logistics and documentation functions of the Company



**Mr. Ashok Vashisht**  
Chief Financial Officer

- He is Fellow member of Chartered Institute of Management Accountants UK & accredited CGMA, Fellow member of CPA Australia, Fellow member of The Institute of Cost Accountants of India and Associate member of The ICSI. He has also done DipIFR from ACCA UK and qualified Independent Director from IICA
- 25+ years of rich professional corporate experience in global and Indian MNCs in the field of Strategy, M&A, Financial Management, Direct & Indirect Taxation, Strategic Cost Management, Project Management, Statutory Audits & Internal Audits, Governance & Risk Management



## Q4 FY23 Financial Highlights

# Q4 FY23: Segment Wise Highlights

## Agrochemical Segment

87%

89%

## Non Agrochemical Segment

13%


11%

% of Revenue


## TOTAL REVENUES

100%



100%



+6%



-13%




+3%


# Q4 FY23: Region Wise Breakup (Agrochemical Segment)

₹ Cr.


## Europe




## NAFTA Region





## TOTAL REVENUES (Agrochemical Segment)



## LATAM Region



## RoW




% of Revenue


# Q4 FY23: Region Wise Breakup (Non Agrochemical Segment)

₹ Cr.

## Europe




## NAFTA Region




## TOTAL REVENUES



(Non - Agrochemical Segment)



## LATAM Region



## RoW




% of Revenue



# Q4 FY23: Financial Highlights

₹ Cr.


## Revenues & GP Margin



Revenue growth led by better product mix & price realization


Gross Margins have improved by 240 basis points due to increased sales in Europe and better margins

## EBITDA & EBITDA Margin\*




EBITDA and EBITDA Margins were impacted due to general inflation and increase in local freight costs

## Profit Before Tax & PBT Margin



PBT has grown by 20% on account of increased Gross Profit Margins and a favourable impact of forex gain during the quarter

## Profit After Tax & PAT Margin



PAT has grown by 18%, led by better product mix & price realization. A favourable impact of forex gain during the quarter also helped to improve margins

\* EBITDA is excluding IA & IAUD write-off (Rs. 5.4 cr. in Q4 FY23; Rs. 17.8 cr. in Q4 FY22)



## **FY23 Financial Highlights**

# FY23 Segment Wise Highlights

## Agrochemical Segment

84%

83%

## Non Agrochemical Segment

16%


17%

% of Revenue


## TOTAL REVENUES

100%



100%



+11%



+21%




+13%


# FY23: Region Wise Breakup (Agrochemical Segment)

₹ Cr.


## Europe




## NAFTA Region




## TOTAL REVENUES (Agrochemical Segment)



## LATAM Region



## RoW




% of Revenue


# FY23: Region Wise Breakup (Non Agrochemical Segment)

₹ Cr.

## Europe




## NAFTA Region




## TOTAL REVENUES


(Non - Agrochemical Segment)



## LATAM Region




## RoW



   % of Revenue

# Impact of weakened Euro to the Dollar in FY23

**USD / Euro Price Chart**



Major currencies have depreciated to the USD in the first six months of the financial year due to the ongoing war between Russia & Ukraine. In the second half of FY23, we have seen a rebound of these currencies.


Over 53% of FY23 Sales from Agrochemical business have been to the Europe whereas majority of the Company's Raw Material is imported from China and payments are done in US Dollar.

This has impacted the Company's Gross Margin and overall profitability as the Euro had considerably depreciated against the dollar.

# FY23: Financial Highlights

₹ Cr.


## Revenues & GP Margin



Revenue growth led by better product mix and price realization.


Gross Margins have been impacted by weakening of €/€ leading to increased input cost mainly in H1 FY23

## EBITDA & EBITDA Margin\*



EBITDA and EBITDA Margins were impacted due to lower GP Margins driven by weakening of €/€ leading to increased input cost, general inflation and strengthening of global workforce to support future growth.


## Profit Before Tax & PBT Margin



PBT was mainly impacted by increased forex losses of Rs. Rs. 58 crores in FY23

Excluding Forex Losses, PBT has grown by 2% in FY23

## Profit After Tax & PAT Margin




PAT de-grew by 2% to Rs. 342 crores for FY23, mainly due to lower profits in H1 FY23

Recommended Final Dividend of Rs. 3 per equity share in addition to interim dividend of Rs. 3 per equity shares, aggregating to Rs. 6 per equity share for FY23


\* EBITDA is excluding IA & IAUD write-off (Rs. 5.4 cr. in Q4 FY23; Rs. 17.8 cr. in Q4 FY22 ; Rs. 11.9 cr. in FY23; Rs. 29.2 cr. in FY22)

# Strong Balance Sheet


## Working Capital (in Days)



## RoCE



## RoE



## Total Equity

**Rs. 2,232 crores**

Rs. 1,912 crores as on Mar'22

## Total Debt

**Rs. 3 crores**

Rs. 38 crores as on Mar'22

## Cash & Cash Equivalents

**Rs. 328 crores\***

Rs. 300 crores as on Mar'22

\* Includes FDs of Rs. 114 crores clubbed in Non Current Other Financial Assets





**Annexure**

# Q4 & FY23 Financial Highlights



Sharda Cropchem Limited

₹ Cr.

Particulars	Q4 FY23	Q4 FY22	Y-o-Y	FY23	FY22	Y-o-Y
<b>Revenue from Operations</b>	<b>1,481.8</b>	<b>1,434.5</b>	<b>3%</b>	<b>4,045.2</b>	<b>3,579.8</b>	<b>13%</b>
COGS	1,013.9	1,015.3		2,860.8	2,499.8	
<b>Gross Profit</b>	<b>467.9</b>	<b>419.2</b>		<b>1,184.4</b>	<b>1,080.0</b>	
<b>Gross Margin %</b>	<b>31.6%</b>	<b>29.2%</b>		<b>29.3%</b>	<b>30.2%</b>	
Employee Expenses	15.2	12.7		44.8	44.2	
Other Expenses	146.4	107.0		438.9	336.4	
<b>EBITDA*</b>	<b>311.8</b>	<b>317.3</b>	<b>-2%</b>	<b>712.6</b>	<b>728.6</b>	<b>-2%</b>
<b>EBITDA Margin %</b>	<b>21.0%</b>	<b>22.1%</b>		<b>17.6%</b>	<b>20.4%</b>	
Forex (Gain)/Loss	-11.9	9.2		57.6	16.5	
Depreciation	67.7	71.7		248.1	245.3	
Other Income	7.0	2.7		40.3	28.9	
<b>EBIT</b>	<b>257.6</b>	<b>221.2</b>	<b>20%</b>	<b>435.3</b>	<b>466.5</b>	<b>-7%</b>
<b>EBIT Margin %</b>	<b>17.4%</b>	<b>15.4%</b>		<b>10.8%</b>	<b>13.0%</b>	
Finance Cost	2.5	0.7		4.5	2.2	
<b>PBT</b>	<b>255.1</b>	<b>220.5</b>	<b>16%</b>	<b>430.7</b>	<b>464.2</b>	<b>-7%</b>
<b>PBT Margin</b>	<b>17.2%</b>	<b>15.4%</b>		<b>10.6%</b>	<b>13.0%</b>	
Tax Expense	56.3	43.5		88.8	115.0	
<b>PAT</b>	<b>198.9</b>	<b>177.0</b>	<b>12%</b>	<b>342.0</b>	<b>349.3</b>	<b>-2%</b>
<b>PAT Margin %</b>	<b>13.4%</b>	<b>12.3%</b>		<b>8.5%</b>	<b>9.8%</b>	
<b>Earnings Per Share (EPS) In Rs.</b>	<b>22.0</b>	<b>19.6</b>		<b>37.9</b>	<b>38.7</b>	

\* EBITDA is excluding IA & IAUD write-off (Rs. 5.4 cr. in Q4 FY23; Rs. 17.8 cr. in Q4 FY22 ; Rs. 11.9 cr. in FY23; Rs. 29.2 cr. in FY22)

# Balance Sheet - Consolidated



Sharda Cropchem Limited

₹ Cr.

EQUITY & LIABILITIES	Mar-23	Mar-22
Equity		
Equity share capital	90.2	90.2
Other equity	2141.8	1822.2
<b>Equity attributable to equity holders of the Company</b>	<b>2,232.0</b>	<b>1,912.5</b>
Non-controlling interests	0.4	0.3
<b>Total Equity</b>	<b>2,232.4</b>	<b>1,912.8</b>
Non-current liabilities		
Financial liabilities		
Lease liabilities	-	3.5
Trade payables		
total outstanding dues of micro enterprises and small enterprises	0.0	0.0
other than micro enterprises and small enterprises	0.0	2.4
Other financial liabilities	1.7	1.6
Provisions	2.7	2.3
Deferred tax liabilities (net)	143.4	128.9
<b>Total non-current liabilities</b>	<b>147.9</b>	<b>138.6</b>
Current liabilities		
Financial liabilities		
Borrowings	3.0	38.0
Lease liabilities	0.0	5.1
Trade payables		
total outstanding dues of micro enterprises and small enterprises	1.9	8.8
other than micro enterprises and small enterprises	1375.7	1168.8
Other financial liabilities	431.4	324.8
Other current liabilities	78.1	55.4
Provisions	61.4	86.7
Income Tax Provisions	19.1	4.2
<b>Total current liabilities</b>	<b>1,970.6</b>	<b>1,691.8</b>
<b>Total Equity &amp; Liabilities</b>	<b>4,350.8</b>	<b>3,743.1</b>

ASSETS	Mar-23	Mar-22
Non-current assets		
Property, plant and equipment	5.0	14.4
Goodwill	0.0	0.0
Intangible assets	663.0	577.4
Intangible assets under development	203.9	212.2
Financial assets		
Other Financial Assets	140.6	11.2
Deferred Tax Assets	7.9	4.9
Income tax assets (net)	72.3	71.6
<b>Total non-current assets</b>	<b>1,092.7</b>	<b>891.7</b>
Current assets		
Inventories	1,134.3	892.8
Financial assets		
Investments	31.9	134.4
Trade receivables	1,833.3	1,540.0
Cash and cash equivalents	176.4	56.7
Bank balance other than cash and cash equivalents	5.5	109.3
Loans	0.0	0.5
Other financial assets	28.7	49.9
Other current assets	48.1	67.9
<b>Total current assets</b>	<b>3,258.2</b>	<b>2,851.5</b>
<b>Total Assets</b>	<b>4,350.8</b>	<b>3,743.1</b>

# Cash Flow Statement




Sharda Cropchem Limited


Particulars (Rs. Cr.)	FY23	FY22
<b>Profit Before Tax</b>	<b>430.7</b>	<b>464.2</b>
Adjustments	266.5	256.9
<b>Operating profit before working capital changes</b>	<b>697.2</b>	<b>721.1</b>
Changes in working capital	-303.7	-379.2
<b>Cash generated from operations</b>	<b>393.5</b>	<b>341.9</b>
Direct taxes paid (net of refund)	-65.3	-74.8
<b>Net Cash from Operating Activities</b>	<b>328.3</b>	<b>267.1</b>
<b>Net Cash from Investing Activities</b>	<b>-145.2</b>	<b>-207.9</b>
<b>Net Cash from Financing Activities</b>	<b>-97.1</b>	<b>-91.0</b>
Exchange difference arising on conversion debited/ (credited) to foreign currency translation reserve (D)	33.0	2.8
<b>Net Change in cash and cash equivalents</b>	<b>119.0</b>	<b>-28.9</b>
Opening Cash Balance	56.7	85.6
Effect of exchange rate changes on cash & cash equivalents held in foreign currencies	0.7	0.0
<b>Closing Cash Balance</b>	<b>176.4</b>	<b>56.7</b>

# Key Financial Performance Indices


## Revenue




## EBITDA & EBITDA Margin\*




## Profit After Tax & PAT Margin




## RoCE



## RoE



## Net Cash & Cash Equivalents^



\* EBITDA is excluding IA & IAUD write-off

^ Total Cash & Cash Equivalents – Debt (Includes FDs of Rs. 114 crores clubbed in Non Current Other Financial Assets)

# Historical Profit & Loss



Sharda Cropchem Limited

₹ Cr.

Particulars	FY23	FY22	FY21	FY20	FY19
<b>Revenue from Operations</b>	<b>4,045.2</b>	<b>3,579.8</b>	<b>2,395.6</b>	<b>2,003.0</b>	<b>1,997.6</b>
COGS	2,860.8	2,499.8	1,636.0	1,388.8	1,387.3
<b>Gross Profit</b>	<b>1,184.4</b>	<b>1,080.0</b>	<b>759.7</b>	<b>614.3</b>	<b>610.2</b>
<b>Gross Margin %</b>	<b>29.3%</b>	<b>30.2%</b>	<b>31.7%</b>	<b>30.7%</b>	<b>30.5%</b>
Employee Expenses	44.8	44.2	37.3	34.9	33.5
Other Expenses	438.9	336.4	305.5	282.4	250.1
<b>EBITDA*</b>	<b>712.6</b>	<b>728.6</b>	<b>455.2</b>	<b>351.7</b>	<b>368.8</b>
<b>EBITDA Margin %</b>	<b>17.6%</b>	<b>20.4%</b>	<b>19.0%</b>	<b>17.6%</b>	<b>18.5%</b>
Forex (Gain)/Loss	57.6	16.5	-19.9	15.1	4.5
Depreciation	248.1	245.3	170.4	137.1	99.4
Other Income	40.3	28.9	45.9	42.1	20.6
<b>EBIT</b>	<b>435.3</b>	<b>466.5</b>	<b>312.2</b>	<b>186.8</b>	<b>243.4</b>
<b>EBIT Margin %</b>	<b>10.8%</b>	<b>13.0%</b>	<b>13.0%</b>	<b>9.3%</b>	<b>12.2%</b>
Finance Cost	4.5	2.2	2.8	1.9	8.4
<b>PBT</b>	<b>430.7</b>	<b>464.2</b>	<b>309.5</b>	<b>184.9</b>	<b>235.0</b>
Tax Expense	88.8	115.0	80.2	20.2	58.7
<b>PAT</b>	<b>342.0</b>	<b>349.3</b>	<b>229.2</b>	<b>164.7</b>	<b>176.3</b>
<b>PAT Margin %</b>	<b>8.5%</b>	<b>9.8%</b>	<b>9.6%</b>	<b>8.2%</b>	<b>8.8%</b>
<b>Earnings Per Share (EPS) In Rs.</b>	<b>37.90</b>	<b>38.71</b>	<b>25.40</b>	<b>18.25</b>	<b>19.55</b>

\* EBITDA is excluding IA & IAUD write-off

# Balance Sheet - Equity & Liabilities



Sharda Cropchem Limited

₹ Cr.

Equities & Liabilities	FY23	FY22	FY21	FY20	FY19
<b>Shareholder's Funds</b>					
Equity and Share Capital	90.2	90.2	90.2	90.2	90.2
Other Equity	2141.8	1,822.2	1,524.1	1,312.6	1,193.7
Non-controlling Interest	0.4	0.3	0.3	0.3	0.2
<b>Total Equity</b>	<b>2,232.4</b>	<b>1,912.8</b>	<b>1,614.6</b>	<b>1,403.1</b>	<b>1,284.1</b>
<b>Non-Current Liabilities</b>					
Borrowings	-	-	-	0.1	0.1
Trade Payables	-	2.4	2.4	2.4	2.9
Lease Liabilities	-	3.5	8.4	-	-
Other Financial Liabilities	1.7	1.6	3.2	13.1	1.4
Provisions	2.7	2.3	3.0	2.7	2.2
Deferred Tax Liabilities (net)	143.4	128.9	92.9	69.3	91.0
<b>Total Non-Current Liabilities</b>	<b>147.9</b>	<b>138.6</b>	<b>109.9</b>	<b>87.5</b>	<b>97.6</b>
<b>Current Liabilities</b>					
Borrowings	3.0	38.0	67.8	0.0	0.0
Lease Liabilities	-	5.1	4.5	-	-
Trade Payables	1,377.6	1,177.6	806.8	686.7	636.2
Other Financial Liabilities	431.4	324.8	149.1	89.7	104.0
Other Current Liabilities	78.1	55.4	58.0	54.4	60.7
Current Tax Liabilities	19.1	4.2	3.2	1.5	0.6
Provisions	61.4	86.7	50.0	24.4	20.1
<b>Total Current Liabilities</b>	<b>1,970.6</b>	<b>1,691.8</b>	<b>1,139.4</b>	<b>856.7</b>	<b>821.7</b>
<b>Total Equity &amp; Liabilities</b>	<b>4,350.8</b>	<b>3,743.1</b>	<b>2,863.9</b>	<b>2,347.2</b>	<b>2,203.3</b>

# Balance Sheet - Assets



Sharda Cropchem Limited

₹ Cr.

ASSETS	FY23	FY22	FY21	FY20	FY19
<b>Assets</b>					
<b>Non-Current Assets</b>					
Property, Plant and Equipment	5.0	14.4	20.9	27.8	13.5
Goodwill	0.0	0.0	0.4	0.4	0.4
Other Intangible assets	663.0	577.4	523.1	388.1	357.8
Intangible assets under development	203.9	212.2	131.0	161.4	219.8
Deferred Tax Assets (net)	7.9	4.9	6.0	3.9	5.5
Non-Current Tax Assets	72.3	71.6	73.6	72.5	49.2
Other financial assets	140.6	11.2	9.4	11.6	8.9
<b>Total Non-Current Assets</b>	<b>1,092.7</b>	<b>891.7</b>	<b>764.5</b>	<b>665.7</b>	<b>655.2</b>
<b>Current Assets</b>					
Inventories	1,134.3	892.8	525.5	382.2	364.9
Investments	31.9	134.4	83.0	115.5	211.9
Trade Receivables	1,833.3	1,540.0	1,162.6	988.4	811.4
Cash & Cash equivalents	176.4	56.7	85.6	77.8	50.6
Other Bank balances	5.5	109.3	175.0	75.7	73.0
Loans	0.0	0.5	-	-	-
Other Financial Assets	28.7	48.9	28.1	11.3	11.9
Other Current Assets	48.1	68.9	39.6	29.6	24.3
<b>Total Current Assets</b>	<b>3,258.2</b>	<b>2,851.5</b>	<b>2,099.3</b>	<b>1,681.5</b>	<b>1,548.2</b>
<b>Total Assets</b>	<b>4,350.8</b>	<b>3,743.1</b>	<b>2,863.9</b>	<b>2,347.2</b>	<b>2,203.3</b>



CSR initiatives taken up by the Company are in the areas of Promoting Education, Healthcare, Eradicating Hunger, Empowerment of Women, Animal Welfare, Promotion of Sports and Rural Development Projects

## Promoting Education



## Animal Welfare



## Medical Aid & Relief

### 'मरीजों की देखभाल सच्चा परमार्थ' राज्यपाल कोशयारी ने युवाओं में बढ़ते नशा पर जताई चिंता

■ प्रसं, मुंबई : राज्यपाल भगत सिंह कोशयारी ने मरीजों की देखभाल को सच्चा परमार्थ बताते हुए कहा कि अगर लोग टीबो के मरीजों को गोद ले और देश को टीबी मुक्त बनाने के लिए मरीजों के पोषण आहार के खर्च का वहन करें, तो यह भी दान होगा। इस दौरान उन्होंने युवाओं में तंबाकू के साथ नशे की बढ़ती प्रवृत्ति पर चिंता जताई। वह परमार्थ रत्न पुरस्कार समारोह में बोल रहे थे।

सामाजिक संस्था परमार्थ सेवा समिति की तरफ से राजभवन में आयोजित पुरस्कार और दीपावली स्नेह कार्यक्रम का आयोजन किया गया था। इसमें राज्यपाल के हाथों टाटा मेमोरियल अस्पताल के निदेशक डॉ. राजेंद्र बडवे और उप निदेशक डॉ. शैलेश श्रीखंडे को कैसर के इलाज, सर्जरी और अनुसंधान में उनके उल्लेखनीय कार्य के लिए परमार्थ रत्न पुरस्कार से सम्मानित किया गया। साथ ही, अविनाश सावले को परमार्थ खेल रत्न पुरस्कार से सम्मानित किया गया। समारोह में राजश्री बिरला विशिष्ट अतिथि थी।

शहरीकरण के साथ बढ़ रहा कैसर: डॉ. राजेंद्र बडवे ने कहा कि भारत



में कैसर की दर पश्चिमी देशों की तुलना में कम है, यह संतोष की बात है। लेकिन, देश में बढ़ते शहरीकरण के साथ कैसर की दर बढ़ रही है। अगर 2035 तक तंबाकू की खेती पूरी तरह से बंद कर दी जाए, तो बड़े पैमाने पर कैसर को नियंत्रित किया जा सकता है, क्योंकि कुल कैसर रोगियों में से तंबाकू के सेवन से होने वाले कैसर रोगियों की संख्या 40 प्रतिशत है। संस्था अध्यक्ष मनमोहन गोयनका ने संस्था की ओर से किए जा रहे कार्यों की रूपरेखा

रखी। संस्था के चेयरमैन लक्ष्मीनारायण वियानी ने 18 मॉडल कोमोथेरेपी सेंटर टाटा मेमोरियल हॉस्पिटल को बनाकर दान में देने की घोषणा की। इस अवसर पर महिला समिति की अध्यक्ष शारदा रामप्रकाश बुवना, बजरंगलाल तापड़िया, महावीरप्रसाद तापड़िया, ज्योतिप्रसाद तापड़िया, दिलीप पिरामल, रवि लालपुरिया, कैलाश अग्रवाल, रमेश पोद्दार सहित बड़ी संख्या में लोग उपस्थित थे।



**EXPLORE...EMERGE...ENHANCE**

**THANK YOU**

**Company: Sharda Cropchem Limited**



*Sharda Cropchem Limited*

CIN: L51909MH2004PLC145007

**Mr. Ashok Vashisht - CFO**

[cfo@shardaintl.com](mailto:cfo@shardaintl.com)

Tel: +91 22 6678 2800

**Investor Relation Advisors: Strategic Growth Advisors Pvt. Ltd.**

**SGA** Strategic Growth Advisors

CIN: U74140MH2010PTC204285

**Mr. Deven Dhruva**

[deven.dhruva@sgapl.net](mailto:deven.dhruva@sgapl.net)

Tel: +91 98333 73300